Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00761761 · ClinicalTrials.gov registry record · Phase 3
Sensoril(Ashwaganhda)for Bipolar Disorder
A Phase 3 study of Bipolar I Disorder and Bipolar II Disorder, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
- 2
- Study locations
NCT00761761 is a Phase 3 study of Bipolar I Disorder and Bipolar II Disorder that has completed, run by University of Pittsburgh. The registered enrollment target is 60 participants, below the 328-participant average among 26 other Bipolar I Disorder trials with a reported enrollment target (82% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT00761761, a Phase 3 study of Bipolar I Disorder and Bipolar II Disorder, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
- 2
- Study locations
Study Summary
The investigators hypothesis is that oral Sensoril® (as compared to placebo) will enhance cognitive abilities (specifically measures of attention, executive function, working memory, and visuospatial ability) in persons with bipolar disorder. Secondarily, the investigators hypothesize there will be secondary improvements in residual mood/anxiety symptoms, and metabolic indices, if impaired (fasting blood glucose and lipids). The investigators aim to test these hypotheses by conducting a randomized, placebo controlled, add on treatment trial of Sensoril® (added to existing mood stabilizer treatment) recruiting 60 subjects with DSM IV-TR bipolar disorder for a period of 8 weeks. Measures of cognition, psychopathology and laboratory indices will be utilized for evaluating primary and secondary outcomes, along with safety assessments.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Sensoril
Study Locations (2)
Pennsylvania
- Western Psychiatric Institute and Clinic University of Pittsburgh Medical Center - Pittsburgh
- Western Psychiatric Institute and Clinic - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2008-10 |
| Est. Completion | 2011-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00761761
The ClinicalTrials.gov registry entry for NCT00761761 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 328-participant average among 26 other Bipolar I Disorder trials with a reported enrollment target (82% lower). The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Bipolar I Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00761761 reports 2 study locations spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00761761 about?
NCT00761761 is a clinical study titled "Sensoril(Ashwaganhda)for Bipolar Disorder". The investigators hypothesis is that oral Sensoril® (as compared to placebo) will enhance cognitive abilities (specifically measures of attention, executive function, working memory, and visuospatial ability) in persons with bipolar disorder. Secondarily, the investigators hypothesize there will be ...
What is the current status of trial NCT00761761?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2008-10. Estimated completion is 2011-03.
What conditions does trial NCT00761761 study?
This clinical trial studies the following conditions: Bipolar I Disorder, Bipolar II Disorder, Bipolar Disorder NOS.
What interventions are being tested in trial NCT00761761?
The interventions under investigation include: Placebo (OTHER), Sensoril (DRUG).
Who is sponsoring clinical trial NCT00761761?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00761761 being conducted?
This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bipolar I Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
RECRUITING · Phase 3
-
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
RECRUITING · Phase 3
-
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
RECRUITING · Phase 3
-
Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex
COMPLETED · Phase 3
-
Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder
COMPLETED · Phase 3
-
A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.